The Manufacturers Life Insurance Company Has $188.24 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

The Manufacturers Life Insurance Company lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 21.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,535,258 shares of the medical equipment provider’s stock after buying an additional 450,190 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Hologic were worth $188,243,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Innealta Capital LLC bought a new stake in Hologic in the 2nd quarter valued at about $25,000. iA Global Asset Management Inc. bought a new position in Hologic in the first quarter worth approximately $37,000. Cranbrook Wealth Management LLC acquired a new stake in Hologic in the second quarter valued at approximately $47,000. Mather Group LLC. bought a new stake in shares of Hologic during the first quarter valued at approximately $48,000. Finally, Massmutual Trust Co. FSB ADV raised its position in shares of Hologic by 24.7% during the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 137 shares during the period. Institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several research reports. Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday. Stephens reaffirmed an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Hologic in a research note on Tuesday, September 17th. Finally, JPMorgan Chase & Co. increased their price objective on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $87.60.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $80.82 on Friday. The company has a market capitalization of $18.86 billion, a PE ratio of 41.23, a PEG ratio of 2.58 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock’s 50 day moving average price is $81.08 and its 200-day moving average price is $77.27. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the previous year, the firm earned $0.93 earnings per share. The business’s revenue was up 2.7% on a year-over-year basis. On average, equities analysts anticipate that Hologic, Inc. will post 4.09 EPS for the current year.

Insider Buying and Selling

In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the transaction, the director now directly owns 45,472 shares in the company, valued at $3,615,024. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,280 shares of company stock worth $1,469,973. Insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.